|
Product Name
|
Strontium Ranelate Heptahydrate
|
|
Batch No.
|
130601SR
|
|
Net Weight
|
300KG
|
|
Mfg. date
|
Jun.27, 2013
|
|
Exp. date
|
Jun.26,2015
|
|
Items
|
Specification
|
Result
|
|
Characters
|
white power slight yellow Crystalline powder, odorless
|
white Crystalline powder
|
|
|
1 the retention time of the main peak should accord with that of the reference standard.
|
conform
|
|
2 The IR spectrum of the sample should accord with that of the reference standard
|
conform
|
|
PH
|
6.50~8.50
|
6.78
|
|
Total Impurities
Individual Impurity
|
≤1.0%
≤0.1%
|
0.05%
0.02%
|
|
Heavy metal
|
≤20ppm
|
conform
|
|
Si
|
30.0%～37.5% (on dried basis)
|
32.3%
|
|
Loss on drying
|
18.0%～23.0%
|
21.8%
|
|
Purity
|
≥99.0
|
99.94%
|
Conclusion: Comply with Enterprise Standard
Application:
Strontium ranelate is used as bone density conservation agents, which mean agents that inhibit bone resorption/favbone mineralization bone regeneration.
It is used to heal bone fractures to treat metabolic bone diseases. Here it is the only antiosteoporotic agent which both increases bone formation reduces bone resorption, resulting in a rebalance of bone turnover in favof bone formation.
It stimulates the calcium sensing receptors leads to the differentiation of pre-osteoblast to osteoblast which increases the bone formation. It also stimulates osteoblasts to secrete osteoprotegerin in inhibiting osteoclasts formed from pre-osteoclasts in relation to the RANKL system, which leads to the decrease of bone resorption.